1. Home
  2. PHI vs ADMA Comparison

PHI vs ADMA Comparison

Compare PHI & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PHI

PLDT Inc. Sponsored ADR

HOLD

Current Price

$23.95

Market Cap

5.2B

ML Signal

HOLD

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

HOLD

Current Price

$16.09

Market Cap

4.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHI
ADMA
Founded
1928
2004
Country
Philippines
United States
Employees
14420
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
4.7B
IPO Year
1953
N/A

Fundamental Metrics

Financial Performance
Metric
PHI
ADMA
Price
$23.95
$16.09
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
N/A
$28.50
AVG Volume (30 Days)
59.0K
2.0M
Earning Date
03-13-2026
03-02-2026
Dividend Yield
5.04%
N/A
EPS Growth
9.36
205.35
EPS
2.32
0.86
Revenue
$3,761,997,877.00
$488,559,000.00
Revenue This Year
$2.70
$22.13
Revenue Next Year
$2.64
$24.15
P/E Ratio
$10.34
$18.80
Revenue Growth
1.69
27.63
52 Week Low
$18.61
$13.50
52 Week High
$25.12
$25.67

Technical Indicators

Market Signals
Indicator
PHI
ADMA
Relative Strength Index (RSI) 63.67 38.99
Support Level $22.34 $15.56
Resistance Level $24.51 $16.65
Average True Range (ATR) 0.48 0.66
MACD 0.09 -0.06
Stochastic Oscillator 77.88 17.59

Price Performance

Historical Comparison
PHI
ADMA

About PHI PLDT Inc. Sponsored ADR

PLDT Inc is the telecommunications carrier in the Philippines. The company's business activities include three business units: Wireless, Fixed Line and Others. The wireless segment consists of mobile telecommunications services provided by Smart and DMPI, and Fixed-line telecommunications services mainly provided by PLDT. It also provides fixed-line services through PLDT's subsidiaries.

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Share on Social Networks: